ATE252913T1 - Vorbeugung einer krankheit mit diabetes charakter - Google Patents

Vorbeugung einer krankheit mit diabetes charakter

Info

Publication number
ATE252913T1
ATE252913T1 AT96921919T AT96921919T ATE252913T1 AT E252913 T1 ATE252913 T1 AT E252913T1 AT 96921919 T AT96921919 T AT 96921919T AT 96921919 T AT96921919 T AT 96921919T AT E252913 T1 ATE252913 T1 AT E252913T1
Authority
AT
Austria
Prior art keywords
diabetes
prevention
type disease
type
disease
Prior art date
Application number
AT96921919T
Other languages
English (en)
Inventor
Thomas Dyrberg
Anne Worsaae
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE252913T1 publication Critical patent/ATE252913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT96921919T 1995-06-30 1996-07-01 Vorbeugung einer krankheit mit diabetes charakter ATE252913T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK76595 1995-06-30
PCT/DK1996/000297 WO1997002043A1 (en) 1995-06-30 1996-07-01 Prevention of a disease having the characteristics of diabetes

Publications (1)

Publication Number Publication Date
ATE252913T1 true ATE252913T1 (de) 2003-11-15

Family

ID=8097303

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921919T ATE252913T1 (de) 1995-06-30 1996-07-01 Vorbeugung einer krankheit mit diabetes charakter

Country Status (7)

Country Link
US (3) US6274549B1 (de)
EP (1) EP0835129B1 (de)
JP (1) JPH11509195A (de)
AT (1) ATE252913T1 (de)
AU (1) AU6299596A (de)
DE (1) DE69630527T2 (de)
WO (1) WO1997002043A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
AU781405B2 (en) * 1998-02-23 2005-05-19 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
IL137904A0 (en) 1998-02-23 2001-10-31 Neurocrine Biosciences Inc Peptide analogues of insulin and pharmaceutical compositions containing the same
JPH11353404A (ja) * 1998-06-11 1999-12-24 Hitachi Ltd 電子カルテシステム
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
WO1997009061A1 (en) 1995-09-06 1997-03-13 Alexion Pharmaceuticals, Inc. Treatment of diabetes via administration of hormonally ineffective insulin

Also Published As

Publication number Publication date
WO1997002043A1 (en) 1997-01-23
EP0835129A1 (de) 1998-04-15
DE69630527T2 (de) 2004-08-05
US20010021696A1 (en) 2001-09-13
DE69630527D1 (de) 2003-12-04
US6274549B1 (en) 2001-08-14
JPH11509195A (ja) 1999-08-17
US20010041669A1 (en) 2001-11-15
EP0835129B1 (de) 2003-10-29
AU6299596A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
FI904414A7 (fi) Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
DE69630527D1 (de) Vorbeugung einer krankheit mit diabetes charakter
EP0236684A3 (en) Galanthamine or analogues thereof for treating alzheimer's disease
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69132035D1 (en) Bandage
SE9500639L (sv) Assistansbordspåse
TR200000134T2 (tr) Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
ATE258797T1 (de) Verwendung von amifostin
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
DE69116224D1 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
ATE117208T1 (de) Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
DE68904794D1 (de) Oesenteil fuer einen haken-oesen-verschluss.
EP1123100A4 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta-estern desselben
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
ES521445A0 (es) Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
FI972674L (fi) 3,3-(disubstituoituja)sykloheksan-1-olimonomeerejä ja vastaavia yhdisteitä
BR9703451C2 (pt) Composto natural para o tratamento de diabete, câncer e etc...
ATE198476T1 (de) Alternative kristallform von tazofelon ((+,-)-5- ((3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl)methyl)-4-thiazolidinon)
ATE100697T1 (de) System und verfahren zum zusammenbau einer orthese.
IT8603418A1 (it) Calzatura anatomica per la prevenzione e la correzione dell'alluce valgo.
IT8603418A0 (it) Calzatura anatomica per la prevenzione e la correzione dell'alluce valgo
BR9401034C1 (pt) Dispositivo de desarme automático para hastes subsoladoras
ES1037506U (es) Pasador perfeccionado para cordones de calzado.
DE68902456D1 (de) Verschluss fuer uhrarmbaender.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties